Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of aNK (Activated NK-92 Natural Killer Cells) Infusions in Combination With ALT-803 (IL-15) in Patients With Stage III (IIIB) or Stage IV Merkel Cell Carcinoma (MCC)

NCT02465957 is registered in ClinicalTrials.gov with ImmunityBio, Inc. as lead sponsor.

NCT NCT02465957
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02465957 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of aNK (Activated NK-92 Natural Killer Cells) Infusions in Combination With ALT-803 (IL-15) in Patients With Stage III (IIIB) or Stage IV Merkel Cell Carcinoma (MCC)
Lead sponsor
ImmunityBio, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
September 24, 2015
Completion date
March 19, 2018
Enrollment
7 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

stage iiib merkel cell carcinoma, stage iv merkel cell carcinoma